These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30771285)

  • 61. Overuse of Cystoscopic Surveillance Among Patients With Low-risk Non-Muscle-invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors.
    Han DS; Lynch KE; Chang JW; Sirovich B; Robertson DJ; Swanton AR; Seigne JD; Goodney PP; Schroeck FR
    Urology; 2019 Sep; 131():112-119. PubMed ID: 31145947
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
    Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
    Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
    Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.
    van der Aa MN; Steyerberg EW; Bangma C; van Rhijn BW; Zwarthoff EC; van der Kwast TH
    J Urol; 2010 Jan; 183(1):76-80. PubMed ID: 19913254
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
    Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
    BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer.
    Duan W; Du L; Jiang X; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Zhang X; Pan H; Yang Y; Wang C
    Oncotarget; 2016 Nov; 7(48):78850-78858. PubMed ID: 27793008
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study.
    Han C; Mengual L; Kang B; Lozano JJ; Yang X; Zhang C; Alcaraz A; Liang J; Ye D
    J Cancer; 2018; 9(17):3208-3215. PubMed ID: 30210644
    [No Abstract]   [Full Text] [Related]  

  • 69. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study.
    Yang H; Li H; Wang Z; Gao J; Guo Y
    Urol Int; 2013; 91(4):456-61. PubMed ID: 23948854
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical Validation of a Urine Test (Uromonitor-V2
    Sieverink CA; Batista RPM; Prazeres HJM; Vinagre J; Sampaio C; Leão RR; Máximo V; Witjes JA; Soares P
    Diagnostics (Basel); 2020 Sep; 10(10):. PubMed ID: 32987933
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.
    Banek S; Schwentner C; Täger D; Pesch B; Nasterlack M; Leng G; Gawrych K; Bonberg N; Johnen G; Kluckert M; Gakis G; Todenhöfer T; Hennenlotter J; Brüning T; Stenzl A;
    Urol Oncol; 2013 Nov; 31(8):1656-62. PubMed ID: 22621963
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of Bladder Epicheck® in the follow-up of high-risk non-muscle-invasive Bladder cancer: A systematic literature review.
    Caño Velasco J; Artero Fullana S; Polanco Pujol L; Lafuente Puentedura A; Subiela JD; Aragón Chamizo J; Moralejo Gárate M; Hernández Fernández C
    Actas Urol Esp (Engl Ed); 2024 May; ():. PubMed ID: 38735433
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
    Du L; Jiang X; Duan W; Wang R; Wang L; Zheng G; Yan K; Wang L; Li J; Zhang X; Pan H; Yang Y; Wang C
    Oncotarget; 2017 Jun; 8(25):40832-40842. PubMed ID: 28388561
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma.
    Mengual L; Burset M; Ribal MJ; Ars E; Marín-Aguilera M; Fernández M; Ingelmo-Torres M; Villavicencio H; Alcaraz A
    Clin Cancer Res; 2010 May; 16(9):2624-33. PubMed ID: 20406841
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predicting results of daily-practice cystoscopies.
    García-Velandria F; Sánchez-García JF; Rodríguez-Toves LA; Alvarez-Buitrago L; Conde-Redondo C; Rodríguez-Tesedo V; Amón-Sesmero JH; Cepeda-Delgado M; Cobos-Carbó A; Alonso-Fernández D; Martínez-Sagarra JM
    Actas Urol Esp; 2014 Oct; 38(8):538-43. PubMed ID: 24612988
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
    Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
    Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
    Mengual L; Lozano JJ; Ingelmo-Torres M; Izquierdo L; Musquera M; Ribal MJ; Alcaraz A
    BMC Cancer; 2016 Feb; 16():76. PubMed ID: 26856686
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma.
    Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
    Cancer; 2001 Dec; 92(11):2820-8. PubMed ID: 11753955
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.
    Wallace E; Higuchi R; Satya M; McCann L; Sin MLY; Bridge JA; Wei H; Zhang J; Wong E; Hiar A; Mach KE; Scherr D; Egerdie RB; Ohta S; Sexton WJ; Meng MV; Weizer AZ; Woods M; Jansz GK; Zadra J; Lotan Y; Goldfarb B; Liao JC
    J Urol; 2018 Mar; 199(3):655-662. PubMed ID: 29061538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.